Cure EB was delighted to be a gold sponsor of EB2026. Attending the congress was a great opportunity to be in the company of brilliant researchers, clinicians, charities, companies and of course and most importantly, families living with EB....
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""]Regular infusions of mesenchymal stromal cells (MSCs) improved symptoms for some children with RDEB, according to results of the Mission EB clinical trial, which was part funded by Cure EB. Published in eClinicalMedicine, the results show that 30...
Cure EB was happy to partner on an EB research priority setting project with the James Lind Alliance and several EB charities....
It's Rare Disease Day! Plus Krystal's Vyjuvek gets a positive opinion from the CHMP!...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""]It was wonderful to have Prof Dimitra Kiritsi, Professor of Dermatology at the Aristotle University of Thessaloniki at our Family Forum online last month. As part of her interesting and informative talk, Dimitra outlined the reasons researchers decided...
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="1/2"][vc_column_text css=""]Thanks to Dr Joanna Jacków who joined us last week to talk about gene editing in EB. Click on the video to watch an excerpt from the webinar where Joanna explains CRISPR gene editing.[/vc_column_text][vc_column_text css=""]You can read...
We were delighted to welcome donors, researchers, clinicians and EB families to our Research Evening at the Royal Institution in London...
The FDA has approved Chiesi's Filsuvez for partial thickness wounds associated with dystrophic (DEB) and junctional epidermolysis bullosa (JEB) in patients 6 months and older. This follows approval of the treatment by the European Commission in June 2022, as well as NICE's recommendation for use...
The National Institute for Health and Care Excellence (NICE) have recommended Filsuvez for the treatment of open wounds in junctional and dystrophic epidermolysis bullosa in the UK....
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization approval for Amryt Pharma’s Filsuvez, a topical gel for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB). Marketing authorization approval is required before a medicine can...